New Clinical Trial: Ibrutinib in Refractory Follicular LymphomaPosted: April 18, 2013
The Weill Cornell Lymphoma Program has recently opened a clinical trial evaluating ibrutinib in men and women with refractory follicular lymphoma. The study sponsor is Janssen Pharmaceuticals, and the principal investigator at Weill Cornell is Dr. Peter Martin. For more information about the study, please call Amelyn Rodriguez, RN at (212) 746-1362 or e-mail Amelyn at firstname.lastname@example.org.
- Age 18 and older
- Refractory follicular lymphoma
- Previously treated with at least 2 prior lines of therapy
- Did not respond to last prior therapy
- Detailed eligibility reviewed when you contact the study team
The purpose of the study is to evaluate the response to treatment with the experimental drug ibrutinib, also called PCI-32765. Ibrutinib is an oral drug that inhibits the enzyme Bruton’s Tyrosine Kinase (BTK), decreasing the ability of lymphoma cells to grow and survive.
All study participants will receive ibrutinib; there is no placebo. Participants will take 4 capsules by mouth once every day. Participants will continue taking ibrutinib as long as they are responding to treatment and not experiencing unacceptable side effects.
Click here to view all current lymphoma trials at Weill Cornell Medical College.